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Abstract
Background:  S100 proteins, a multigenic family of non-ubiquitous cytoplasmic Ca2+-binding
proteins, have been linked to human pathologies in recent years. Dysregulated expression of S100
proteins, including S100A9, has been reported in the epidermis as a response to stress and in
association with neoplastic disorders. Recently, we characterized a regulatory element within the
S100A9 promotor, referred to as MRE that drives the S100A9 gene expression in a cell type-
specific, activation- and differentiation-dependent manner (Kerkhoff et al. (2002) J. Biol. Chem. 277,
41879–41887).
Results: In the present study, we investigated transcription factors that bind to MRE. Using the
MRE motif for a pull-down assay, poly(ADP-ribose)polymerase-1 (PARP-1) and the heterodimeric
complex Ku70/Ku80 were identified by mass spectrometry and confirmed by chromatin
immunoprecipitation. Furthermore, TPA-induced S100A9 gene expression in HaCaT keratinocytes
was blocked after the pharmacologic inhibition of PARP-1 with 1,5-isoquinolinediol (DiQ).
Conclusion: The candidates, poly(ADP-ribose)polymerase-1 (PARP-1) and the heterodimeric
complex Ku70/Ku80, are known to participate in inflammatory disorders as well as tumorgenesis.
The latter may indicate a possible link between S100 and inflammation-associated cancer.
Background
Members of the S100 protein family comprise a multi-
genic group of non-ubiquitous cytoplasmic Ca2+-binding
proteins of the EF-hand type, differentially expressed in a
wide variety of cell types. In particular, S100A8 and
S100A9 also known as calgranulins are abundant in mye-
loid cells. The expression of S100A8 and S100A9 is
increased in various disorders, such as rheumatoid arthri-
tis, inflammatory bowel disease and vasculitis [1]. The
S100/calgranulins are associated with inflammatory dis-
orders as they are secreted from phagocytes upon cellular
activation [2,3], and track disease activity. In addition to
their abundance in myeloid cells, S100A8 and S100A9
can also be found in the epidermis as a response to stress.
For example, they are significantly up-regulated in differ-
entiating suprabasal wound keratinocytes [4,5], in
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response to UVB irradiation [6], and in psoriasis keratino-
cytes [7], suggesting a role for these proteins in the patho-
genesis of certain diseases. Based on these findings, the
two S100 proteins have been referred to as stress-regulated
proteins [8].
An additional important indication for their involvement
in inflammatory and neoplastic disorders is that most
S100 genes are found near a region on human chromo-
some 1q21 which is responsible for a number of chromo-
somal abnormalities [9,10]. This results in a dysregulated
expression of S100A9 as well as other S100 genes associ-
ated with neoplasias [11]. Although the function of S100
proteins in cancer cells in most cases is still unknown, the
specific expression patterns of these proteins is a valuable
prognostic tool. In addition, a psoriasis susceptibility
region, the PSORS4 locus, is mapped to chromosome
1q21 [12].
Despite a number of distinct regulatory regions located
upstream of the transcription initiation site that are
known to either activate or repress promoter activity of
S100 genes in a differentiation and tissue/cell-specific
manner, the corresponding nuclear factors as well as the
underlying molecular mechanisms still remain unclear
[13]. In addition to PU.1 [14], C/EBP-α and -β [15] have
been shown to drive S100A9 gene expression in the mye-
loid lineage. Recently, cytokine oncostatin M (OM) has
been demonstrated to strongly induce the S100A9 gene
expression [16]. Promoter analysis provided evidence that
S100A9 represents a novel OM-regulated gene acting
through the STAT3-signaling cascade. This finding is in
accordance with another study showing that IL-22 up-reg-
ulates the expression of S100A7, S100A8, and S100A9 in
keratinocytes since IL-22 induces STAT3 activation in
keratinocytes [17].
In a previous study, we identified a regulatory element
within the S100A9 promoter referred to as MRP regulatory
element (MRE) that drives the S100A9 gene expression in
a cell-specific and differentiation-dependent manner [13].
This regulatory region is located at position -400 to -374
bp, and two distinct nuclear complexes were demon-
strated to bind to this region. Interestingly, the formation
of the nuclear protein complexes closely correlates with
the myeloid-specific expression of the S100A9 gene and,
were therefore referred to as MRE-binding complex A
(MbcA) and MbcB, respectively. Analysis of one of the two
nuclear complexes revealed a heterocomplex consisting of
transcriptional intermediary factor 1β (TIF1β) and a yet
unidentified protein with homology to KRAB domain-
containing (Kruppel-related) zinc finger proteins (ZFP)
[13].
In order to identify the other nuclear complex we per-
formed DNA affinity chromatography studies employing
MRE oligonucleotides as an affinity matrix. Further exten-
sive investigations provide strong evidence that a complex
of PARP-1, Ku70 and Ku80 was involved in the regulation
of the S100A9 gene expression. This finding was con-
firmed by chromatin immunoprecipitation (ChIP) analy-
sis.
Results and discussion
Identification of MRE-binding proteins
In order to identify the proteins participating in the for-
mation of the complex we performed DNA affinity chro-
matography. Nuclear extracts of Raji cells were subjected
to affinity purification employing MRE oligonucleotides
as an affinity matrix. Nuclear proteins bound to MRE were
eluted in a stepwise gradient with 0, 100, and 1,000 mM
NaCl and then analyzed by EMSA. Only the proteins of
the 1 M NaCl eluate displayed DNA-binding activity, indi-
cating that they specifically interacted with the probe (Fig.
1A). The binding of proteins to MRE was specific, as an
excess of non-labeled MRE oligonucleotide efficiently
competed with the labeled probe in complex formation,
whereas the mutant oligonucleotide MRE
(T386C,G385T,A380C,A379C) did not compete (Fig.
1B). Our previous study showed that this MRE mutant oli-
gonucleotide was unable to compete for binding to MRE
oligonucleotide [13].
Then the proteins of the 1 M NaCl eluate were precipitated
using the UPPA Concentrate Kit, then subjected to SDS-
PAGE, and finally visualized by Coomassie staining (Fig.
1C).
Seven protein bands with apparent molecular weights of
110, 75, 65, 60, 35, and 25-kDa were detected. The pro-
tein bands were excised from the gel, digested with
trypsin, and subjected to MALDI-MS for peptide mass fin-
gerprint and to ESI-MS/MS for peptide sequencing. The
data obtained were analyzed using Swissprot and NCBI
databases. The identified proteins are summarized in
Table 1.
Specifically, PARP-1 (113 kDa) was identified in band 1
by peptide mass fingerprint and peptide sequencing (Tab.
2). Fragments of PARP-1 were found in nearly all bands,
especially in band 7 (Fig. 2). Ku80 (83 kDa) was identi-
fied in band 2 (Tab. 3 and Fig. 3) and Ku70 (70 kDa) in
band 3 by peptide mass fingerprint and peptide sequenc-
ing (Tab. 4). The identity of PARP-1 and Ku80 was also
confirmed by Western Blotting (see Additional file 1).
PARP-1 represents a nuclear enzyme with a DNA nick sen-
sor function [18]. Upon binding to broken DNA, PARP
becomes activated and cleaves NAD+ into nicotinamideBMC Molecular Biology 2006, 7:48 http://www.biomedcentral.com/1471-2199/7/48
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(A) DNA affinity chromatography Figure 1
(A) DNA affinity chromatography. Nuclear proteins (20 mg total protein) were prepared from Raji cells, and subjected to 
DNA affinity chromatography with the biotinylated MRE oligonucleotide (position -400 to -357 bp). Proteins specifically bound 
to MRE were eluted with different NaCl concentrations, and 10 μl-aliquots (800 μl total) were analyzed by EMSA. (B) Com-
petition EMSA analysis. For competition analysis of MRE-binding, either unlabelled MRE oligonucleotide or MRE mutant oli-
gonucleotide was added at a 100-fold molar excess to the binding reactions. (C) Separation of the proteins bound to 
MRE. The 1M NaCl eluate of affinity chromatography was precipitated with UPPA-Protein Concentrate Kit according to the 
manufacturer's protocol. The precipitate was dissolved in SDS-PAGE sample buffer and subjected to SDS-PAGE (Ready-Gel 
gradient gel 4–15% (Biorad, Munich, Germany). The proteins were stained by Coomassie R250 The proteins are numbered 
according their molecular weights.
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and ADP-ribose. It then polymerizes ADP-ribose on
nuclear acceptor proteins including histones, transcrip-
tion factors, and PARP itself [18]. Poly ADP-ribosylation
has been implicated in a number of cellular processes,
such as DNA repair [19], transcriptional regulation [20-
22], and cell cycle progression [22]. Excessive PARP acti-
vation induced by oxidative stress has been shown to
decrease cellular NAD+ and ATP pools, resulting in cell
dysfunction or necrotic cell death [23-25]. The PARP acti-
vation pathway contributes to tissue injury in various
forms of shock, inflammation, trauma, and reperfusion
injury, as indicated by the protection provided by PARP
inhibitors or the PARP-/- phenotype in these disease mod-
els [25].
Both Ku80 and Ku70 form the heterodimeric DNA bind-
ing complex Ku that was originally identified two decades
ago as a major target of autoantibodies in Japanese
patients with the scleroderma-polymyositis overlap syn-
drome [26]. The autoantibodies against Ku have since
been found in subsets of patients suffering from a number
of different autoimmune diseases, including systemic
lupus erythematosus and scleroderma.
Ku is best known for its crucial role in DNA repair [27]. Ku
is involved in both major pathways of DNA double strand
break repair: homologous recombination and non-
homologous end joining. Besides its vital role in DNA
repair, reports have implicated Ku in certain other cellular
processes, including telomere maintenance, antigen
receptor gene arrangements, cell cycle regulation, regula-
tion of heat shock-induced responses, and specific gene
transcription and apoptosis. For example, it has been
shown that Ku is required for interleukin-13/-4-induction
MS/MS spectrum of [M+2H]2+ at m/z = 7504 assigned to pep- tide AA 66–78 of PARP-1 measured in the digest of band 7 Figure 2
MS/MS spectrum of [M+2H]2+ at m/z = 750.4 assigned 
to peptide AA 66–78 of PARP-1 measured in the 
digest of band 7. Ion series y and b were labeled according 
to [54].
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Table 1: Summary of proteins identified by peptide mass fingerprint and peptide sequencing
Band (molecular weight) Proteins, abbreviation, and SwissProt accession number Number of sequenced peptides
1 (110 kDa) - Poly (ADP-ribose) polymerase 1 (PARP-1; P09874) 3 (m)
2 (75 kDa) - ATP-dependent helicase II (Ku80; P13010) 1 (m)
3 (65 kDa) - ATP-dependent helicase II (Ku70; P12956) 2 (m)
4 (60 kDa) - PARP-1
- Ku70
- Keratin
2 (LC)
2 (LC)
5 (50 kDa) - PARP-1
- Keratin
6 (LC)
6 (35 kDa) - DNA-(apurinic or apyrimidine site) lyase (APEX1; P27695)
- Glyceraldehyde-3-phosphate hydrogenase (GAPDH; P04406)
9 (LC)
3 (LC)
7 (25 kDa) - PARP-1 9 (LC)
Labels "m" refer to verification by manual ESI-MS/MS and "LC" to HPLC-MS/MS, respectively.
Table 2: MALDI-MS results of PARP-1
PARP-1
Amino acid residues [M+h]+
1–15 MAESSDKLYRVEYAK 1700.85 (AcetN)
66–78 HPDVEVDGFSELR 1499.71
109–119 TLGDFAAEYAK 1185.57
109–122 TLGDFAAEYAKSNR 1542.76
168–182 EEL GFRPEYSASQLK 1753.88
332–340 EWVTPKEFR 1191.62
487–496 AEPV EVVAPR 1066.58
637–654 KFYPLEIDYGQDEEAVKK 2172.09
638–654
or 637–653
FYPLEIDYGQDEEAVKK
KFYPLEIDYGQDEEAVK
2043.99
685–700 AMVEYEIDLQKMPLGK 1896.95 (2 MetOx)
848–858 YKP FKQLHNRR 1484.72
858–865 RLL WHGSR 1024.58
866–878 TTNFA GILSQGLR 1377.75
879–893 IA PPEAPVTGYM FGK 1593.80 (MetOx)
Peptides in bold were sequenced with MS/MS on the doubly charged 
ion. MetOx refers to peptides with oxidized methionines.BMC Molecular Biology 2006, 7:48 http://www.biomedcentral.com/1471-2199/7/48
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of 15-lipoxygenase-1 gene expression in human epithelial
cells [28]. Here, Ku is induced in response to IL-13 and IL-
4, and a 29 bp region within the -353 to -304 bp region of
the 15-LO-1 promoter is required for its binding and sub-
sequent induction of 15-LO-1 gene expression.
Studies with cells and/or animals deficient in Ku have
shown that dysfunction and dysregulation of the above-
mentioned processes lead to tumor development [27]. In
addition, a rare microsatellite polymorphism in the Ku80
gene is associated with cancer in patients with varying
radiosensitivity [29].
Since PARP-1 and Ku bind to DNA double strand breaks
we performed DNA affinity chromatography employing
the MRE mutant oligonucleotide MRE
(T386C,G385T,A380C,A379C) as affinity matrix in order
to verify whether this binding is specific to the MRE
sequence. Our previous study showed that this MRE
mutant oligonucleotide was unable to compete for bind-
ing to MRE oligonucleotide [13]. We failed to detect DNA-
binding activity in the corresponding 1 M NaCl eluate,
and after protein precipitation, no protein bands were vis-
ualized by Coomassie staining (data not shown), indicat-
ing that the high affinity of PARP-1 and KU to DNA
double strand breaks was not responsible for their bind-
ing to the MRE oligonucleotide.
ChIP experiment
To verify whether PARP-1 and Ku80 can directly bind to
the S100A9 promoter in vivo, we performed chromatin
immunoprecipitation. Cross-linked chromatin from Raji
cells was immunoprecipitated with specific antibodies
against PARP-1, Ku80, and the nonspecific antibodies
MS/MS spectrum of [M+2H]2+ at m/z = 659.34 assigned to peptide AA 131–141 of Ku80 measured in the digest of band 2 Figure 3
MS/MS spectrum of [M+2H]2+ at m/z = 659.34 assigned to peptide AA 131–141 of Ku80 measured in the digest 
of band 2. For further details see legend to Figure 2.
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Table 3: MALDI-MS results of Ku80
Ku80
Amino acid residues [M+h]+
36–44 KVITMFVQR 1137.65 (1MetOx)
37–44 VITMFVQR 1009.55 (1MetOx)
131–141 HIEIFTDLSSR 1317.68
354–363 RFFMGNQVLK 1255.66 (1MetOx)
355–363 FFMGNQVLK 1099.56 (1MetOx)
401–413 ANPQVGVAFPHIK 1377.76
470–486 TDTLEDLFPTTKIPNPR 1958.02
641–654 AFREEAIKFS EEQR 1739.87
649–660 FSEEQRFNNFLK 1558.77
Peptides in bold were sequenced with MS/MS on the doubly charged 
ion. MetOx refers to peptides with oxidized methionines.BMC Molecular Biology 2006, 7:48 http://www.biomedcentral.com/1471-2199/7/48
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IgG. After PCR analysis using S100A9 promoter-specific
oligonucleotides, we found that PARP-1 and Ku80 specif-
ically bind the regulatory region of S100A9 promoter.
Chromatin immunoprecipitates with nonspecific IgG
antibodies did not reveal any specific binding to the ana-
lyzed regulatory regions (Fig. 4).
Thus, the ChIP experiments clearly confirmed that both
PARP-1 and Ku80 specifically bind to MRE. It is likely that
PARP-1 and Ku80 (together with Ku70) are components
of the nuclear complex that binds to MRE. This assump-
tion is supported by several reports demonstrating the
interaction of PARP-1 with Ku proteins. A complex
formed by PARP-1, Ku proteins and C/EBPα has been
shown to be involved in the increasing sensitivity of pros-
tate cancer cells to DNA damage [30].
Strong evidence that PARP-1 is involved in S100A9 gene
regulation has also recently reported by Martin-Oliva and
co-workers [31]. They showed that TPA-induced S100A9
gene expression was blocked after the pharmacologic
inhibition of PARP-1 with 3,4-dihydro-5- [4-(1-piperidi-
nyl)butoxyl]-1(2H)-isoquinolinone. In accordance with
this finding, they also did not observe TPA-induced
S100A9 gene expression in parp1 knockout mice. There-
fore, we investigated S100A9 gene expression in HaCaT
keratinocytes in the absence and presence of the PARP-1
inhibitor 1,5-isoquinolinediol (DiQ). Both TPA- and
TNFα- stimulation resulted in increased levels of S100A9
mRNA transcripts. S100A9 gene expression was n1.45= 2.7-
fold increased after TPA treatment and n3.94= 15.3-fold
increased after TNFα stimulation, respectively (Fig. 5).
While the TPA-increased S100A9 gene expression was
completely abrrogated by DiQ, TNFα-induced S100A9
gene expression was not affected by DiQ. Together with
the report of Martin-Oliva and co-workers [31], these
findings indicate the involvement of PARP-1 in S100A9
gene regulation.
Further correlations of PARP-1 and S100A9 gene expres-
sion are found in other reports: Dazard and co-workers [6]
reported that in addition to other genes, S100A9 gene
expression is up-regulated in normal human epidermal
keratinocytes in response to ultraviolet B radiation (UVB).
Induction of S100A9 gene expression is also found in epi-
thelial cells in specific pathophysiological conditions,
S100A9 gene expression in HaCaT cells after TPA (A) and  TNFα (B) stimulation Figure 5
S100A9 gene expression in HaCaT cells after TPA 
(A) and TNFα (B) stimulation. HaCaT cells were stimu-
lated with either 100nM TPA or 50 ng/ml TNFα in the pres-
ence and absence of DiQ (20 μM) for 18 h. Then total RNA 
was extracted from the cells, and S100 gene expression anal-
ysis was performed by quantitative PCR analysis. Relative 
S100 gene expression is expressed in relation to the corre-
sponding S100 gene expression in non stimulated cells: ΔΔCT 
S100 (stimulated) = ΔCT S100 (stimulated) – ΔCT S100 (non-
stimulated). The number of experiments was n = 3.
Table 4: MALDI-MS results of Ku70
Ku70
Amino acid residues [M+h]+
101–115 NIYVLQELDN PGAKR 1729.92
115–129 RILELDQFKGQQGQK 1787.06
116–129 ILELDQFKGQQGQK 1631.86
116–130 ILELDQFKGQQGQKR 1787.06
302–318 TFNTSTGGL LLPSDTKR 1807.96
326–339 QIILE KEETEELKR 1757.96
446–461 MPFTE KIMATPEQVG K 1838.90 (2 MetOx)
471–488 FTYRSDSFENPVLQQHFR 2271.09
475–488 SDSFENPVLQQHFR 1703.81
Peptides in bold were sequenced with MS/MS on the doubly charged 
ion. MetOx refers to peptides with oxidized methionines.
ChIP with specific antibodies against PARP-1 and Ku80 Figure 4
ChIP with specific antibodies against PARP-1 and 
Ku80. ChIP was performed on chromatin from Raji cells, 
using antibodies as indicated. PCR was performed using prim-
ers specific for the S100A9 promoter as described in the 
methods section.
Std.
IgG
anti-PARP1
anti-Ku80BMC Molecular Biology 2006, 7:48 http://www.biomedcentral.com/1471-2199/7/48
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such as wound healing [4,5] and psoriasis [7]. Similarly,
PARP-1 activity is increased after UV irradiation and in
psoriasis [32]. Our finding that PARP-1 regulates the
S100A9 gene expression represents the first link between
this nuclear protein and the S100 protein family.
What is the molecular mechanism by which PARP-1 regu-
lates S100A9 gene expression?
Roles for PARP-1 in the transcriptional regulation of spe-
cific genes have been demonstrated in several physiologi-
cal contexts [33-35]. From these studies, at least two
different mechanisms have been proposed for the regula-
tion of transcription by PARP-1: (1) modulating chroma-
tin structure, and (2) acting as part of gene-specific
enhancer/promoter-binding complexes. As a component
of enhancer/promoter-binding complexes, PARP-1 acts to
stimulate transcription with some activators, while inhib-
iting transcription with others, depending on the cell type
and promoter context. In some cases, PARP-1 enzymatic
activity is not required for its transcriptional co-regulator
function (e.g., with NF-κB). Recently, Ju and co-workers
[36] have presented some mechanistic details of how
PARP-1 acts as a modulator of the chromatin structure: In
complex with DNA topoisomerase IIβ (TopoIIβ), PARP-1
is recruited to specific promoter regions. Then, transient
dsDNA break formation mediated by TopoIIβ induces
PARP-1 enzymatic activity, which is required for a nucleo-
some-specific histone H1-high-mobility group B
exchange event and for local changes of chromatin archi-
tecture. The authors conclude that TopoIIβ/PARP-1 com-
plex-mediated transient dsDNA breaks serve as a general
mechanism for regulated initiation of gene transcription
by nuclear receptors and other classes of DNA binding
transcription factors, including AP-1.
AP-1 has been assumed to be involved in S100A9 gene
expression [31,37,38], and poly(ADP ribosyl)ation of AP-
1 by PARP-1 appears to be important for its binding activ-
ity as shown by Martin-Oliva and co-workers [31]. Phar-
macological inhibition of PARP-1 results in significant
reduction of the relative levels of AP-1-binding activity
compared to mice treated with TPA [31]. In contrast, NF-
κB activation was not reduced by PARP-1 inhibitors but
reduced in parp-1-/- cells [31,39,40]. It has been reported
that in addition to NF-κB, AP-1 is also induced by TNFα
receptor ligation [41]. In the present study, however, we
demonstrated that TPA-increased S100A9 gene expression
was blocked by the PARP-1 inhibitor, while TNFα-
increased S100A9 mRNA level was not affected. These
findings might indicate that both interaction of PARP-1
with transcription factors and PARP-1 mediated
poly(ADP ribosyl)ation are important for S100A9 gene
expression.
It is noteworthy to point to the association of S100 pro-
teins with tumorgenesis. An increasing body of evidence
provided by several reports shows that S100 gene are dif-
ferentially regulated in various cancer cells [16,42-53].
PARP-1 and Ku have also been assigned a role in tumor-
genesis. Therefore, this study provides first insights into
the molecular mechanism of S100A9 gene regulation, and
it opens an avenue for a better understanding as to why
S100 gene expression is associated with tumor promo-
tion. Nevertheless, we are aware that the exact elucidation
of the DNA/protein complexes will require further inten-
sive investigations.
Conclusion
The observations reported here demonstrate the role of
PARP-1 (and probably Ku70/80) in S100A9 gene regula-
tion. The association of S100 proteins with inflammatory
and neoplastic disorders together with the role of PARP-1
in stress response and tumorgenesis might indicate the
link between S100 and inflammation-associated cancer.
Methods
Nuclear Extraction and Electrophoretic Mobility Shift 
Assays (EMSAs)
Nuclear extracts of Raji cells were essentially prepared as
described earlier [13]. For the EMSA reaction, a double-
stranded oligonucleotide coding for bp -400 to -357 of the
S100A9 promoter was used. The sense oligonucleotide
CAGACCATCCTTGTTGGACTAAAAGGAAGGGGCA-
GACTGCCATG and its antisense strand
CATGGCAGTCTGCCCCTTCCTTTTAGTCCAACAAGGAT-
GGTCTG were annealed and end-labeled by T4 polynucle-
otide kinase and [γ-32P] ATP (Hartmann Analytic,
Braunschweig, Germany). EMSAs were performed with
nuclear extracts as follows: nuclear protein (50 μg) was
mixed with 3 μg of sheared genomic salmon sperm DNA
and 100,000 cpm of the labeled probe (approximately 1
ng) in EMSA buffer [20 mmol/L Hepes (pH 7.5), 1 mmol/
L MgCl2, 75 mmol/L KCl, 1 mmol/L DTT, 0.018% (v/v)
Nonidet P-40] in a total volume of 36 μl. This mixture was
allowed to incubate for 60 min at 4°C. Samples were
mixed with 12 μl of sample buffer [50% (w/v) sucrose, 0.5
× TBE (where 1 × TBE buffer is 90 mmol/L Tris/borate, 2
mmol/L EDTA, pH 8.0)] and then run on a non-denatur-
ing 5% polyacrylamide gel in 0.25 × TBE buffer. The gels
were dried and exposed to Kodak XAR-5 X-ray film.
For competition analysis of MRE-binding, either unla-
belled MRE oligonucleotide or a MRE mutant oligonucle-
otide was added at a 100-fold molar excess to the binding
reactions.
DNA affinity chromatography
The biotinylated MRE oligonucleotides were synthesized
by Applied Biosystems Oligo Factory (Weiterstadt, Ger-BMC Molecular Biology 2006, 7:48 http://www.biomedcentral.com/1471-2199/7/48
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many). For DNA affinity purification, 5–20 mg nuclear
protein was incubated with 4 nmol double-stranded,
biotinylated MRE oligonucleotide and 570 μg sheared
genomic salmon sperm DNA in 6,000 μl EMSA-buffer.
After rotating the samples for 1 hour at 4°C, 4 ml Immu-
nopure Immobilizied Streptavidin (Pierce Biotechnology,
Rockford, IL, USA) was added and further incubated for 1
h at 4°C. Then the sample was applied to an empty PD10
column and the proteins bound to MRE beads were eluted
with EMSA-buffer supplemented with 0, 100, and 1,000
mM NaCl. Aliquots of the different fractions were ana-
lyzed by EMSA as well as subjected to SDS-PAGE using
standard protocols.
Protein concentration and SDS-PAGE
The affinity chromatography eluate (460 μl) was precipi-
tated with UPPA-Protein Concentrate™ Kit (Geno Tech-
nology, Inc., St. Louis, MO, USA) according to the
manufacturer's protocol. The precipitate was dissolved in
SDS-PAGE sample buffer (0,125 M Tris at pH 6,8, 4%
SDS, 10% (v/v) β-mercaptoethanol, 20% (v/v) glycerol,
0,02% (w/v) bromophenol blue). SDS-PAGE (Ready-Gel
gradient gel 4–15% (BioRad, Munich, Germany) was per-
formed with running buffer using standard protocols. The
gel was stained with Coomassie R250 (4% (w/v) in 44%
methanol, 9.2% acetic acid).
Protein digestion and Mass Spectrometry (MS)
Stained protein bands were excised, destained in 25 mM
ammonium bicarbonate containing 50% methanol,
rinsed with acetic acid/methanol/water 10/45/45 (v/v/v)
and then shrunk with acetonitrile and dried. Digestion
solution (30 ng/μl trypsin sequencing grade (Roche, Pen-
zberg, Germany) in 10 mM ammonium bicarbonate at
pH 9) was applied to each gel piece until swelling was
complete (i.e. 10–15 μl depending on gel size). Digestion
buffer was added to cover the gel pieces. After overnight
digestion at 37°C, peptides were extracted using increas-
ing concentrations of acetonitrile containing 5% formic
acid (50%, 80%, 100% subsequently) and desalted with
μC18 ZipTips (Millipore, Bedford, MA, USA) according to
the manufacturer's protocol.
For peptide mapping, a matrix assisted laser desorption/
ionization time-of-flight (MALDI-TOF) instrument Tof-
Spec 2E (Waters/Micromass, Manchester, UK) was used in
positive ion reflectron mode. 0.5 μl of peptide mixture
and 0.5 μl of 4-hydroxy-α-cyano cinnamic acid (10 mg/
ml in 50% acetonitrile and 0,05% trifluoro acetic acid)
were spotted and mixed on the MALDI target. For meas-
urement, ion suppression was set to 500 and spectra were
externally calibrated and internally corrected by trypsin
autolysis peaks.
For peptide sequencing with collision induced dissocia-
tion an electrospray ionization (ESI) ion trap mass spec-
trometer Esquire3000 (Bruker Daltonics, Bremen,
Germany) was used. For manual nanospray measure-
ments a modified liquid-junction ion source and home-
made omega-glass capillaries were employed. Digestion
was measured in 50% methanol/5% acetic acid. For
HPLC-MS/MS, peptides were separated on a 75 μm ID
C18 column (PepMap, LC Packings, Amsterdam, The
Netherlands) using a 30 min gradient from 5% to 100%
solvent B (solvent A: 0.05% formic acid/acetonitrile (95/
5, v/v), solvent B: 0.04% formic acid/acetonitrile (20/80,
v/v)) at a flow rate of 250 nl/min.
Peptide mass fingerprints and sequence data were
searched against the databases SwissProt (Swiss Institute
of Bioinformatics) and NCBI (National Center for Bio-
technology Information, USA) employing the Mascot
search engine (Matrix Science LTD, London, UK).
Formaldehyde cross-linking and chromatin 
immunoprecipitation
DNA and proteins were cross-linked by the addition of
formaldehyde (1% final concentration) 10 min before
harvesting, and cross-linking was stopped by the addition
of glycine pH 2.5 (125 μM final concentration) for 5 min
at room temperature. Cells were centrifuged, resuspended
in hypotonic buffer, and passed through a 26-gauge nee-
dle. Nuclei were spun down, resuspended in 300 μl of
SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl,
pH 8, and a protease inhibitor mixture), and sonicated to
generate 500-2000 bp fragments. After centrifugation, the
cleared supernatant was diluted 10-fold with immunopre-
cipitation buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl,
5 mM EDTA, 0.5% Nonidet P-40). The cell lysate was pre-
cleared by incubation at 4°C with 15 μl of protein G
beads preadsorbed with sonicated single-stranded DNA
and bovine serum albumin. The cleared lysates were incu-
bated overnight with polyclonal antibodies against PARP-
1 and Ku80, or with nonspecific IgG antibody. Immune
complexes were precipitated with 30 μl of protein G beads
preadsorbed with sonicated single-stranded DNA and
bovine serum albumin. After centrifugation the beads
were washed, and the antigen was eluted with 1% SDS
and 100 mM sodium carbonate. DNA-protein cross-links
were reversed by heating at 65°C for 4–5 h, and DNA was
phenol-extracted and ethanol-precipitated. Then PCR
analysis was performed using S100A9 promoter-specific
oligonucleotides. For PCR analysis, oligonucleotides
encompassing bp -435 to -415 (forward primer: 5'-
AGTATCACAGAGCCAGGCAAG-3') and bp -215 to -196
(reverse primer:5'-GTTTGCAGGAAGCTGGTTGT-3') of
the S100A9 promoter was used.BMC Molecular Biology 2006, 7:48 http://www.biomedcentral.com/1471-2199/7/48
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Quantitative PCR
HaCaT cells were stimulated as indicated. Then total RNA
was extracted from cells using the RNA Isolation Kit (Qia-
gen, Germany) and first strand cDNA was synthesized
according to common molecular biology techniques. The
level of mRNA transcripts for S100A9 was estimated by
real-time PCR using forward primer 5'- GGAATTCAAA-
GAGCTGGTGCG-3'and reverse primer 5'-GCATTTGT-
GTCCAGGTCCTCC-3'. CT  values of target genes were
normalized to GAPDH. Relative S100 gene expression is
expressed in relation to the corresponding S100 gene
expression in non stimulated cells: ΔCT S100 (stimulated)
– ΔCT S100 (non-stimulated) = ΔΔCT S100 (stimulated).
Abbreviations
DiQ, 1,5-isoquinolinediol; ESI, electrospray ionization;
HPLC, high performance liquid chromatography; MALDI,
matrix-assisted laser desorption/ionization; MRE, mrp14
promoter regulatory element; MS, mass spectrometry;
TOF, time-of-flight; TopoIIβ, DNA topoisomerase IIβ
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